Literature DB >> 7671940

Circadian growth hormone secretion in short multitransfused prepubertal children with thalassaemia major.

G Katzos1, F Harsoulis, M Papadopoulou, M Athanasiou, K Sava.   

Abstract

UNLABELLED: Growth hormone (GH) secretion was determined by evaluating circadian GH profiles for 24 h and GH responses to clonidine stimulation test and insulin-stimulated hypoglycaemia (ITT), in nine prepubertal children with beta-thalassaemia major (TM) and 17 with non-GH deficient short stature (NGHDSS). The TM children were multitransfused and had early and intensive chelation therapy. All patients had normal hypoglycaemia to ITT, with peak GH levels of 15.71 +/- 5.86 ng/ml for children with NGHDSS and 13.91 +/- 7.20 ng/ml for children with TM. Peak GH levels during a clonidine test were 17.54 +/- 5.30 and 17.15 +/- 1.38 ng/ml, respectively. The GH peak parameters such as the number of peaks, the integrated GH concentration and the area under the curve (AUC) were similar in both groups of children and reflected the total 24-h secretion and the daily and nocturnal secretion separately. An abnormal 24-h GH profile compatible with the diagnosis of endogenous neurosecretory GH dysfunction was found in only two out of nine children with TM and in four out of seven children with NGHDSS.
CONCLUSION: Our data suggest that growth hormone neurosecretory dysfunction is not a universal finding in children with thalassaemia major but might depend on the degree of iron deposit in the pituitary.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7671940     DOI: 10.1007/bf02029352

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  25 in total

1.  Neurosecretory dysfunction of growth hormone secretion in thalassemia major.

Authors:  N Shehadeh; A Hazani; M C Rudolf; I Peleg; A Benderly; Z Hochberg
Journal:  Acta Paediatr Scand       Date:  1990 Aug-Sep

2.  Swelling and lysis of rat liver mitochondria induced by ferrous ions.

Authors:  F E HUNTER; J M GEBICKI; P E HOFFSTEN; J WEINSTEIN; A SCOTT
Journal:  J Biol Chem       Date:  1963-02       Impact factor: 5.157

3.  Serum somatomedin A in chronic renal failure.

Authors:  K Takano; K Hall; K W Kastrup; N Hizuka; K Shizume; K Kawai; M Akimoto; T Takuma; N Sugino
Journal:  J Clin Endocrinol Metab       Date:  1979-03       Impact factor: 5.958

Review 4.  Clinical review 11: The rational use of growth hormone during childhood.

Authors:  S D Frasier; B M Lippe
Journal:  J Clin Endocrinol Metab       Date:  1990-08       Impact factor: 5.958

5.  Incidence of neurosecretory dysfunction among children aged 6-14 years in Rehovot, Israel.

Authors:  Z Zadik; A Kowarski
Journal:  Acta Paediatr Scand Suppl       Date:  1989

6.  Growth and sexual maturation in thalassemia major.

Authors:  C Borgna-Pignatti; P De Stefano; L Zonta; C Vullo; V De Sanctis; C Melevendi; A Naselli; G Masera; S Terzoli; V Gabutti
Journal:  J Pediatr       Date:  1985-01       Impact factor: 4.406

7.  Algorithms for the study of episodic hormone secretion.

Authors:  G R Merriam; K W Wachter
Journal:  Am J Physiol       Date:  1982-10

8.  Hormonal changes in thalassaemia major.

Authors:  D M Flynn; A Fairney; D Jackson; B E Clayton
Journal:  Arch Dis Child       Date:  1976-11       Impact factor: 3.791

9.  Growth hormone (GH) provocative testing frequently does not reflect endogenous GH secretion.

Authors:  B B Bercu; D Shulman; A W Root; B E Spiliotis
Journal:  J Clin Endocrinol Metab       Date:  1986-09       Impact factor: 5.958

10.  Depressed serum somatomedin activity in beta-thalassemia.

Authors:  P Saenger; E Schwartz; A L Markenson; J H Graziano; L S Levine; M I New; M W Hilgartner
Journal:  J Pediatr       Date:  1980-02       Impact factor: 4.406

View more
  6 in total

1.  Osteoporosis and beta-thalassemia major: role of the IGF-I/IGFBP-III axis.

Authors:  A Lasco; N Morabito; A Gaudio; A Crisafulli; A Meo; G Denuzzo; N Frisina
Journal:  J Endocrinol Invest       Date:  2002-04       Impact factor: 4.256

Review 2.  Growth and endocrine function in thalassemia major in childhood and adolescence.

Authors:  M Delvecchio; L Cavallo
Journal:  J Endocrinol Invest       Date:  2010-01       Impact factor: 4.256

Review 3.  Growth hormone therapy for people with thalassaemia.

Authors:  Chin Fang Ngim; Nai Ming Lai; Janet Yh Hong; Shir Ley Tan; Amutha Ramadas; Premala Muthukumarasamy; Meow-Keong Thong
Journal:  Cochrane Database Syst Rev       Date:  2017-09-18

4.  Growth hormone secretion in polytransfused prepubertal patients with homozygous beta-thalassemia. Effect of long-term recombinant GH (recGH) therapy.

Authors:  A Masala; M M Atzeni; S Alagna; D Gallisai; C Burrai; M G Mela; P P Rovasio; P Gallo
Journal:  J Endocrinol Invest       Date:  2003-07       Impact factor: 4.256

5.  Growth hormone therapy for people with thalassaemia.

Authors:  Chin Fang Ngim; Nai Ming Lai; Janet Yh Hong; Shir Ley Tan; Amutha Ramadas; Premala Muthukumarasamy; Meow-Keong Thong
Journal:  Cochrane Database Syst Rev       Date:  2020-05-28

6.  Thalassaemia and aberrations of growth and puberty.

Authors:  Andreas Kyriakou; Nicos Skordis
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-07-27       Impact factor: 2.576

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.